Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A public workshop organized by the FDA and MRA
Acting Commissioner Ned Sharpless will return to lead the National Cancer Institute.
Implants are extensively tested before approval to demonstrate safety and effectiveness. Still, there are risks associated with all implants
The indication is for people with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with prior chemotherapy regimens.
The approval is based on data from CASSIOPEIA, an open-label, randomized, active-controlled phase 3 study.
The FDA has found a probable cancer-causing contaminant in generic drugs shipped from abroad––most recently, Zantac (ranitidine).
The FDA has been investigating NDMA and other nitrosamine impurities in blood pressure and heart failure medicines.
The FDA is warning that these drugs used to treat advanced breast cancers may cause rare but severe inflammation of the lungs.
FDA says studies of new breast cancer treatments should allow enrollment of men as well as women.
This is the second drug the FDA has approved for myelofibrosis; the first came in 2011.
pembrolizumab’s efficacy was investigated in two clinical trials of people with recurrent, locally advanced or metastatic disease.
All Biocell textured breast implants will be pulled because they may increase the risk for a certain type of blood cancer.
Researchers reached this conclusion after reviewing data on more than 30,000 people.
Darzalex in combination with lenalidomide and dexamethasone is for people who are ineligible for an autologous stem cell transplant.
The Food and Drug Administration may approve the next site-agnostic treatment in August.
An immunocompromised patient died from invasive infections after an investigational fecal microbiota transplant.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.